scholarly journals Nek2 siRNA therapy using a portal venous port–catheter system for liver metastasis in pancreatic cancer

2016 ◽  
Vol 107 (9) ◽  
pp. 1315-1320 ◽  
Author(s):  
Toshio Kokuryo ◽  
Shigeru Hibino ◽  
Kazushi Suzuki ◽  
Katsutaka Watanabe ◽  
Yukihiro Yokoyama ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Liver Metastasis ◽  
Port Catheter ◽  
Venous Port ◽  
Catheter System ◽  
Sirna Therapy

Assessment of the Antithrombogenicity of a Poly-2-Methoxyethylacrylate-Coated Central Venous Port-Catheter System

2020 ◽  
Vol 43 (5) ◽  
pp. 775-780 ◽  
Author(s):  
Shuji Kariya ◽  
Miyuki Nakatani ◽  
Yasuyuki Ono ◽  
Takuji Maruyama ◽  
Yutaka Ueno ◽  
...  
Keyword(s):  
Port Catheter ◽  
Central Venous ◽  
Central Venous Port ◽  
Venous Port ◽  
Catheter System

scholarly journals A rare cause of stroke: fail-implanted venous port catheter system – a case report

BMC Neurology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Mesut Yeniguen ◽  
Tobias Braun ◽  
Alexander Vlazak ◽  
Thomas Umscheid ◽  
Martin Juenemann ◽  
...  
Keyword(s):  
Case Report ◽  
Cerebral Infarction ◽  
Subclavian Artery ◽  
Left Subclavian Artery ◽  
Acute Onset ◽  
Port Catheter ◽  
System A ◽  
Venous Port ◽  
First Case ◽  
Catheter System

Abstract Background We present the case of a 75-year-old female with acute embolic cerebral infarction caused by a fail-implanted venous port catheter system in the left subclavian artery. Case presentation A 75-year-old woman presented to our emergency room after acute onset of a right-sided hemiparesis and dysarthria. Within 2 days after admission, she developed a left-sided hemiparesis, ataxia with concordant gait disturbance and incoordination of the left upper limb. DWI-MRI showed acute multiple infarcts in both cerebral and cerebellar hemispheres. Laboratory examination, 24-h Holter electrocardiography and transthoracic echocardiography provided no pathological findings. Further examination revealed an arterially fail-implanted port catheter, placed in the left subclavian artery with its tip overlying the ascending aorta, as the source of cerebral embolism. Conclusion This is the first case report of thromboembolic, cerebral infarction due to a misplaced venous port catheter in the subclavian artery, emphasizing the imperative need for a thorough diagnostic workup, when embolism is suspected but cannot be proven at first glance.

Effects of celebrex and zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in syrian hamsters

2001 ◽  
Vol 37 ◽  
pp. S110
Author(s):  
F.A. Wenger ◽  
M. Kilian ◽  
I. Schimke ◽  
H. Guski ◽  
C.A. Jacobi ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Liver Metastasis ◽  
Syrian Hamsters

TIMP1 expression underlies sex disparity in liver metastasis and survival in pancreatic cancer

2021 ◽  
Vol 218 (11) ◽  
Author(s):  
Chris D. Hermann ◽  
Benjamin Schoeps ◽  
Celina Eckfeld ◽  
Enkhtsetseg Munkhbaatar ◽  
Lukas Kniep ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Liver Metastasis ◽  
Mouse Models ◽  
Pancreatic Tumors ◽  
Primary Tumors ◽  
Increased Risk ◽  
Metastasis Development ◽  
Male Specific ◽  
Sex Disparity ◽  
Timp1 Expression

Sex disparity in cancer is so far inadequately considered, and components of its basis are rather unknown. We reveal that male versus female pancreatic cancer (PC) patients and mice show shortened survival, more frequent liver metastasis, and elevated hepatic metastasis-promoting gene expression. Tissue inhibitor of metalloproteinases 1 (TIMP1) was the secreted factor with the strongest male-biased expression in patient-derived pancreatic tumors. Male-specific up-regulation of systemic TIMP1 was demonstrated in PC mouse models and patients. Using TIMP1-competent and TIMP1-deficient PC mouse models, we established a causal role of TIMP1 in determining shortened survival and increased liver metastasis in males. Observing TIMP1 expression as a risk parameter in males led to identification of a subpopulation exhibiting increased TIMP1 levels (T1HI males) in both primary tumors and blood. T1HI males showed increased risk for liver metastasis development not only in PC but also in colorectal cancer and melanoma. This study reveals a lifestyle-independent sex disparity in liver metastasis and may open new avenues toward precision medicine.

scholarly journals LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of Pancreatic Cancer: Erratum

Theranostics ◽  
2021 ◽  
Vol 11 (20) ◽  
pp. 10171-10172
Author(s):  
Biao Zheng ◽  
Jianhua Qu ◽  
Kenoki Ohuchida ◽  
Haimin Feng ◽  
Stephen Jun Fei Chong ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Liver Metastasis ◽  
Survival Outcome ◽  
Poor Survival ◽  
Poor Survival Outcome ◽  
High Liver

Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer

2003 ◽  
Author(s):  
Gaku Matsumoto ◽  
Shigenori Nagai ◽  
Mariko Muta ◽  
Koji Tsuruta ◽  
Atsutake Okamoto ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Liver Metastasis ◽  
Survival Benefit ◽  
Immune Therapy ◽  
Metastasis Model

Vascular access by physician assistants: evaluation of an implantable peripheral port system in cancer patients.

1995 ◽  
Vol 13 (6) ◽  
pp. 1513-1519 ◽  
Author(s):  
E B Rubenstein ◽  
A Fender ◽  
K V Rolston ◽  
L S Elting ◽  
P Prasco ◽  
...  
Keyword(s):  
Vascular Access ◽  
Physician Assistants ◽  
Ambulatory Setting ◽  
Infusion Therapy ◽  
Port Catheter ◽  
New Device ◽  
Access System ◽  
Catheter System ◽  
Port System

PURPOSE To determine the ability of a physician assistant (PA) to insert, in an ambulatory setting, a peripheral subcutaneous implanted vascular-access device (VAD) and to evaluate the ability to transfer this training to a second PA. We also evaluated the performance and complications associated with this new device. PATIENTS AND METHODS The Peripheral Access System (PAS) Port catheter system (Sims-Deltec Inc, St Paul, MN) was inserted in patients who required long-term (> 3 months) vascular access for infusion therapy. RESULTS The first PA (PA-1) successfully inserted 57 of 62 devices (92%) after gaining experience with the technique in 10 patients (success rate, five of 10 [50%]; P = .003). The second PA (PA-2) was successful in eight of 10 initial attempts (80%) and 25 of 30 overall (83%). Complications were few and limited to phlebitis, thrombosis, and a low infection rate (0.2 per 1,000 catheter days). CONCLUSION PAs can be taught to insert a peripheral subcutaneous implanted VAD. This technique is transferable from one PA to another, and the device studied is appropriate for outpatient VAD programs.

A Phase I/Ib trial of Ad-REIC in liver cancer: study protocol

2019 ◽  
Vol 15 (31) ◽  
pp. 3547-3554 ◽  
Author(s):  
Astushi Oyama ◽  
Hidenori Shiraha ◽  
Daisuke Uchida ◽  
Masaya Iwamuro ◽  
Hironari Kato ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Liver Metastasis ◽  
Phase I ◽  
Liver Tumor ◽  
Objective Response ◽  
University Hospital ◽  
Open Label ◽  
Safety And Efficacy ◽  
Immortalized Cells ◽  
Dose Limiting Toxicity

This study will assess the safety and efficacy of the administration of adenoviral vector expressing the human-reduced expression in immortalized cells (Ad-REIC) to a liver tumor in patients with hepatocellular carcinoma (HCC) or liver metastasis of pancreatic cancer. A Phase I clinical study of Ad-REIC administration to a liver tumor in a patient with HCC or liver metastasis of pancreatic cancer will be conducted. The study is a single-arm, prospective, nonrandomized, noncomparative, open-label, single-center trial performed in Okayama University Hospital, Okayama, Japan. Ad-REIC will be injected into the liver tumor under ultrasound guidance. Ad-REIC administration will be repeated a total of three-times every 2 weeks. The primary end point is the dose-limiting toxicity and incidence of adverse events. The secondary end points are the objective response rate and disease control rate. This study aims to expand the indication of Ad-REIC by assessing its safety and efficacy in patients with HCC or liver metastasis of pancreatic cancer.

Sign in / Sign up

Export Citation Format

Share Document